目的 探討津力達(dá)顆粒聯(lián)合利拉魯肽注射液治療2型糖尿病的臨床療效。方法 選取2014年7月—2016年7月漯河市中心醫(yī)院收治的2型糖尿病患者90例為研究對(duì)象，所有患者采用計(jì)算機(jī)隨機(jī)分為對(duì)照組和治療組，每組各45例。對(duì)照組皮下注射利拉魯肽注射液，起始劑量為0.6 mg/次，根據(jù)空腹血糖水平調(diào)節(jié)用量至1.2 mg/次，至少一周后將劑量增加為1.8 mg/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服津力達(dá)顆粒，1袋/次，3次/d。兩組患者均連續(xù)治療12周。觀察兩組的臨床療效，比較兩組的血糖相關(guān)指標(biāo)、氧化應(yīng)激指標(biāo)和血清學(xué)指標(biāo)。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為82.22%、95.56%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組空腹血糖（FBG）、餐后2 h血糖（2 hPG）、糖化血紅蛋白（HbA1c）、空腹胰島素（FINS）、丙二醛（MDA）水平顯著降低，超氧化物歧化酶（SOD）和谷胱甘肽過(guò)氧化物酶（GSH-Px）水平顯著升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組顆粒蛋白前體（PGRN）、富含半胱氨酸的酸性分泌蛋白（SPARC）、單核細(xì)胞趨化蛋白-1（MCP-1）和血管細(xì)胞間黏附分子-1（VCAM-1）水平顯著降低，分泌型卷曲相關(guān)蛋白-5（SFRP5）水平顯著增加，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 津力達(dá)顆粒聯(lián)合利拉魯肽注射液治療2型糖尿病具有較好的臨床療效，可改善氧化應(yīng)激狀態(tài)，降低機(jī)體炎癥反應(yīng)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Jinlida Granules combined with Liraglutide Injection in treatment of type 2 diabetes mellitus. Methods Patients (90 cases) with type 2 diabetes mellitus in Luohe Central Hospital from January 2013 to February 2015 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were sc administered with Liraglutide Injection, starting dose 0.6 mg/time, after a week, dose adjustment to 1.8 mg/time, once daily. Patients in the treatment group were po administered with Jinlida Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and blood glucose related indexes, oxidative stress indexes, and serological indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.22% and 95.56%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of FBG, 2 hPG, HbA1c, FINS SOD, and GSH-Px in two groups were significantly decreased, but the levels of MDA in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of PGRN, SPARC, MCP-1, and VCAM-1 in two groups were significantly decreased, but the levels of SFRP5 in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Jinlida Granules combined with Liraglutide Injection has clinical curative effect in treatment of type 2 diabetes mellitus, can improve the state of oxidative stress, reduce the inflammatory response, which has a certain clinical application value.